Another Ebola Vaccine Among New Filings At EMA
Four New EU Marketing Applications Granted Fast-Track Status
The European Medicines Agency has received 11 new marketing authorization applications, including three for orphan products from Vertex, MYR Pharmaceuticals and AstraZeneca.
You may also be interested in...
The reimbursement deal will allow cystic fibrosis patients as young as two years of age to access Orkambi in France for the first time.
Janssen’s two investigational Ebola vaccines are among four new products recently granted fast-track review by the European Medicines Agency. GlaxoSmithKline and Viiv Healthcare are not disclosing the outcomes of accelerated assessment requests they have made.